KRAS and familial pancreatic carcinoma: A previous study of palbociclib in KRAS mutant pancreatic cancer cell lines showed concern that though palbociclib monotherapy inhibited cell proliferation, it appeared to also increase epithelial mesenchymal transition (EMT) in cell lines with wild-type SMAD4 [48].